Erdmann, S., Kirchner, M., Götte, H., & Kieser, M. (2020). Optimal designs for phase II/III drug development programs including methods for discounting of phase II results. BMC medical research methodology, 20, . https://doi.org/10.1186/s12874-020-01093-w
Cita Chicago Style (17a ed.)Erdmann, Stella, Marietta Kirchner, Heiko Götte, y Meinhard Kieser. "Optimal Designs for Phase II/III Drug Development Programs Including Methods for Discounting of Phase II Results." BMC Medical Research Methodology 20 (2020). https://doi.org/10.1186/s12874-020-01093-w.
Cita MLA (9a ed.)Erdmann, Stella, et al. "Optimal Designs for Phase II/III Drug Development Programs Including Methods for Discounting of Phase II Results." BMC Medical Research Methodology, vol. 20, 2020, https://doi.org/10.1186/s12874-020-01093-w.